Biopharma Innovations Summit Day 2
Join us for an exclusive two-day event where Agilent will showcase cutting-edge biopharma solutions.
The first day of the event we will explore Agilent’s comprehensive portfolio for the spectrum of applications from drug discovery to quality control. Learn more about our cell analysis and genomics expertise and the tools we provide to drive IVT mRNA development, protein therapeutics and cell and gene therapies
The second day will focus on advanced analytical solutions, including HRMS for tRNA sequencing and LC/MS for DNA/RNA analysis. Learn how to scale up oligonucleotide purification with Agilent biocolumns, which enhance the efficiency and accuracy of your processes.
By attending this event you will:
Gain insights from Agilent to optimize biotherapeutic workflows, including rigorous quality testing in cGMP environments and handling nucleic acid, vaccines, mAB and protein samples.
Understand how metabolic analyses can impact CAR cell function and behavior, using cytolytic cell killing assays on the xCELLigence system to develop cell therapy processes and confirm product potency.
Learn about new techniques in high-resolution LC/MS for analyzing tRNA modifications.
Discover software tools available for high-resolution MS systems in both research and QA/QC labs.
Compare analytical and semipreparative LC purification methods for synthetic oligonucleotides, gaining competitive insights into purification strategies.
Talk 1: Advanced Analytical Solutions for Nucleic Acid Analysis and Purification
- Presented by Dr. Charlotte Lekieffre, Biopharma Application Specialist, Agilent Technologies
The emphasis during the second day of the Summit will be on advanced analytical solutions, such as HRMS for tRNA sequencing and LC/MS for DNA/RNA analysis. Additionally, you’ll discover techniques to enhance the efficiency and accuracy of your processes by scaling up oligonucleotide purification using Agilent biocolumns.
Talk 2: Extracted Yeast tRNA Sequencing by LC-MS/MS
- Presented by Aurore Attina, Engineer of Mass Spectrometry, University of Montpellier
RNA modifications are essential for RNA stability, maturation, and functionality; directly influencing protein translation and gene regulation. They play a central role in various biological processes and are associated with many diseases, including cancers and neurological disorders. tRNA (transfer RNA), which plays a key role in protein synthesis, is the most modified molecule in the organism known to date. tRNA modifications are essential to ensure their correct function in protein translation, maintain the accuracy and fidelity of the genetic code, and enable flexible adaptation to changing cellular conditions and are therefore a crucial attribute to monitor. To monitor and map these modifications of tRNA, we have developed a LC-HRMS analytical workflow, first using synthetic oligonucleotide for the method optimization. In this webinar, we will first go through the various steps involved in LC-MS/MS method optimization using synthetic oligonucleotides. In a second part, we will present the protocol development of an enzymatic digestion applied to tRNA extracted from yeast. This digestion generates oligonucleotide fragments that can be analyzed by LC-MS/MS for sequence confirmation.
Talk 3: Discover Agilent’s Software Tools to Confirm Oligonucleotide Sequence Integrity
- Presented by Dr. Holger Stalz, LC/MS Product Specialist Austria & Switzerland, Agilent Technologies
Mass spectrometry (MS) is increasingly important for the development of therapeutic modalities such as oligonucleotides. A common analytical method for large molecules is intact mass by LC/MS. This can be used for the characterization and identification of a product or process-related impurities, or simply as a confirmation of molecular weight. The newly introduced Agilent OpenLab CDS 2.8 SW version comes with a set of features to enable the automatization of biopharma workflows. If you want to know how LC/MSD Spectral Deconvolution of your biopharma samples can be automated, we will provide answers during our presentation. Even more details on Oligonucleotide sequence confirmation and impurities characterization can be acquired using the power of a high-resolution accurate mass system (HRAM) on the Agilent 6545XT AdvanceBio LC/Q-TOF. Analyzing the sample data with the software workflows in Agilent BioConfirm version 12 will support the user to get the trusted answers to their most relevant questions.
Talk 4 Maximize Your Resources and Simplify Scale-up with AdvanceBio Oligonucleotide Columns
- Presented by Dr. Andrea Tripodi, Application Development Engineer, Agilent Technologies
Several classes of nucleic acids, such as antisense oligonucleotides, small interfering RNAs (siRNAs), and aptamers are being investigated for potential therapeutic applications. Synthetic oligonucleotides inevitably contain many impurities due to limitations in the efficiency of each chemical reaction used during manufacture. They include deletion sequences (missing one or more nucleotides) and reaction by-products often arising during the final deprotection or cleavage steps. Ion pair reversed-phase (IP-RP) chromatography stands out as the prevalent method for analyzing and purifying oligonucleotides. For increased resolution and separation of your full-length synthetic oligonucleotide from closely related impurities, AdvanceBio Oligonucleotide is the ideal choice. The latest developments include semi-preparative, and lab-scale preparative columns packed with superficially porous particles that provide excellent performance and resolution without compromising column loading. A fast and easy scale-up method from analytical to semi-preparative scale was successfully achieved using a 10 mm ID column enabling higher sample loading using the same analytical LC instrument.
